PARK NICOLLET FRAUENSHUH CANCER CENTER & HEALTHPARTNERS CANCER CARE CENTERS

RANDY HURLEY, MD
Medical Director
HealthPartners and Regions Hospital Cancer Care Centers
randy.w.hurley@healthpartners.com

MARK A. WILKOWSKE, MD
Medical Director
Park Nicollet Frauenshuh Cancer Center
mark.wilkowske@parknicollet.com

LAURA HOLASEK
Administrative System Director
Oncology Services
HealthPartners and Park Nicollet
laura.holasek@parknicollet.com
Expert, compassionate care that’s close to home

HealthPartners Cancer Care Centers and Park Nicollet Frauenshuh Cancer Center believe in caring for the whole patient. We do that by providing the highest quality comprehensive care and focusing on timely appointments so patients and families can quickly get the answers they need. We’re also committed to furthering cancer care through expanded research and access to extensive clinic trials right here in the metro area. Our physicians and care teams are inspired by our patients to offer the best possible care. Our 2018 annual report highlights that dedication to providing expert, compassionate care that’s close to home.

When facing a potentially life-altering diagnosis such as cancer, patients and families need immediate answers to their questions. We stand by our 48-hour promise. This is our commitment to see a patient within 48 hours of a cancer diagnosis. To further support access, Richard Peterson, MD, Neuro Oncologist, will begin seeing patients with brain tumors at Park Nicollet.

Our ongoing commitment to research is reinforced by the recent announcement of the Oncology Research Center led by Dylan Zylla, MD, MS. This center combines our longstanding areas of research under one umbrella to better serve a larger number of patients. We are actively involved in a number of research trials and projects, including continuing research on the effectiveness of medical cannabis in easing patient discomfort. Our newly created center includes all Phase 1, 2 and 3 clinical trials. Phase 1 clinical trials, led by Arkadiusz Dudek, MD, offer patients access to emerging treatment options without traveling to faraway institutions. We’re grateful to our foundations and donors for their support of our research efforts.

We continue to grow and build partnerships across the Twin Cities and Western Wisconsin. We would like to recognize Hutchinson Health as our newest partner. We continue our longstanding tradition of high quality, compassionate care and innovative treatment options to help support our patients and the communities we serve. Our high standards in caring and supporting the whole patient is demonstrated by our certification from the American College of Surgeons’ Commission on Cancer and participation in the American Society of Clinical Oncology’s Quality Oncology Practice Initiative.

If you have questions about this report or the exceptional care we strive to offer every patient, please contact us.
Cancer care locations

MINNESOTA
1. HealthPartners Riverside Cancer Care Center
2. Lakeview Hospital Cancer Care
3. Park Nicollet Clinic & Specialty Center
   Burnsville Infusion Center
4. Park Nicollet Clinic & Specialty Center
   Maple Grove Infusion Center
5. Park Nicollet Frauenshuh Cancer Center
6. Regions Hospital Cancer Care Center
7. St. Francis Cancer Center
8. Hutchinson Health
   NEW – Welcomed into our family of care in 2018

WISCONSIN
9. Amery Hospital and Clinic
   Cancer Center of Western Wisconsin*
10. Hudson Hospital
    Cancer Center of Western Wisconsin*
11. Osceola Medical Center
    Cancer Center of Western Wisconsin*
12. St. Croix Regional Medical Center
    Cancer Center of Western Wisconsin*
13. Western Wisconsin Health
    Cancer Center of Western Wisconsin*
14. Westfields Hospital
    Cancer Center of Western Wisconsin*

*HealthPartners provides physician services in partnership with Cancer Center of Western Wisconsin
Highlights of 2018

NEW ONCOLOGY RESEARCH CENTER WILL ALIGN, CENTRALIZE EFFORTS

Dylan Zylla, MD, MS – Has been named medical director of the newly created Oncology Research Center. The center will align and centralize the areas of oncology research from HealthPartners Cancer Care Centers and Fraeneshuh Cancer Center to improve efficiencies and collaboration. This new role is in addition to his other leadership roles as a physician and researcher.

Dr. Zylla is a high energy, innovative and collaborative leader with a passion for symptom management research and quality improvement. He recently won the Association of Community Cancer Centers’ innovation award for leading an 18-month project, Establishment of Personalized Pain Goals in Oncology Patients to Improve Care and Decrease Costs. He is also studying other ways to improve quality of life in patients with cancer through his ongoing projects evaluating medical cannabis, mu-opioid receptor expression, electronic patient-reported outcomes and hyperglycemia management during chemotherapy.

He will be teamed with Michele Lacy, RN, OCN, who will be assuming the role of administrative director along with her duties as the administrative director of Metro-Minnesota Community Oncology Research Consortium (MMCORC). Michele’s excellent operational leadership skills and ability to build strong relationships will be a major asset. Together, they will be accountable for leading and supporting the work of the new Oncology Research Center.

NEW STAFF

One of the strengths of our program is talented, dedicated colleagues. In 2018, we welcomed several new members to our team.

Caroline Abenakyo, MA, NP-C
Sarah Benthein, RN
Janet Brock, RN
Xee Cha, RMA
Cynthia Crotty, RN
Jina Hagen
Allison Heald, RN
Lauren Hellstrom, RN
Julie Heyd, MS, BA, CTR
Carrie Hickey, RN
Lisa Huset, PA-S
Geleyna Jones
Malibu Korkalo, RN
Heather Leland, RN, BSN
Beverly Lubemier
Lori McAre
Nora Nashawaty
Alexandra Neppsund, RN
Therese Otten, MA
Ashely Peetsch, RN
Rachel Recknagel, EMIC, RN
Cierre Sroda, PA-C
Somu Suppiah, MD
Lisa Tucker, CMA
Kimberly Woodman, RN, BSN

AWARDS AND ACHIEVEMENTS

Balkrishna Jahagirdar, MD – Recognized for his leadership to the Minnesota Society of Clinical Oncology (MSCO) with a lifetime achievement award. This award honored his lifelong commitment and dedication to improving the quality of life and care for oncology and hematology patients in Minnesota.

Randy Hurley, MD – Received the excellence in education award from Rein in Sarcoma, an organization dedicated to research, patient support and education. Dr. Hurley was honored for his ongoing passion and knowledge about sarcoma education.

Dawn McDougal Miller, MME, MT-BC – Accepted a lifetime achievement award from Music Therapy Association of Minnesota (MTAM), a group that strives to enhance quality music therapy services.

Anne Nelson, RN and Lori Christian, RN – Received the Good Catch for Patient Safety Award from the Minnesota Hospital Association.

Grateful Patient is a program at Regions Hospital that allows patients and family members to recognize and thank staff who made a difference in their lives. Several members of the oncology staff were recipients.

• Randy Hurley, MD
• Ciarra Sroda, AC-P
• Emina Mujcic, RN
Leadership in professional organizations

MINNESOTA SOCIETY OF CLINICAL ONCOLOGY
We continue to provide leadership and support to the Minnesota Society of Clinical Oncology. This group works to provide advocacy for patients with cancer and promote standards of excellence for high-quality cancer care.

Secretary/Treasurer:
Priya Kumar, MBBS, MS

Educational Program Chair and Lifetime Achievement Award:
Balkrishna Jahagirdar, MD

Member-at-Large:
Yan Ji, MD

Member-at-Large:
Melissa M. Sherman, MD

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY
This group develops and conducts clinical trials, as well as researches methods to alleviate side effects of cancer and cancer treatments.

Principal Investigator, Board Member and Co-Chair, community oncology committee:
Dan Anderson, MD

Experimental therapeutics committee:
Balkrishna Jahagirdar, MD

Neuro-oncology committee:
Richard Peterson, MD

METRO MN ONCOLOGY NURSING SOCIETY
We’re proud to have several colleagues in leadership roles in an organization dedicated to promoting their profession, colleagues and patients.

President or President-elect:
Adina Peck, ANP, GNP

Secretary:
Mary Ehresman, FNP, ADCN

Treasurer:
Cindy Jacobson, RN, ONC

Director-at-Large:
Nancy Anson, RN, ONC

Director-at-Large:
Mary Holland, BSN, OCN

NEW CREDENTIALS
Team members mastered additional skills and received oncology certified nursing credentialing.

Amy Feist, RN, OCN
Jenny Graves, RN, OCN
Patti Schmidt, RN, OCN
Amber Voss, RN, OCN
Community awareness and support

HealthPartners and Park Nicollet oncology programs are actively involved in programs to increase cancer screenings, community awareness and support for cancer patients.

**A Breath of Hope Lung Foundation**
This organization fights lung cancer by funding innovative research, raising awareness and supporting patients and families. We partnered with them at a number of events in 2018.

- **Minnesota Thought Leader’s Meeting**
  Joined this city-wide work group with the goal of increasing the number of Minnesotans screened for lung cancer.

- **Annual Walk/Run**
  Sponsored this event, including staffing an information booth, in Minneapolis in August 2018.

- **Shining Bright Gala**
  Engaged in this November event.

- **Lung Cancer Summit**
  Participated in a one-day summit for those impacted by lung cancer. The goal is to provide education and resources to lighten the burden of cancer for patients and caregivers.

**Open House at Park Nicollet Frauenshuh Cancer Center**
Celebrated an expansion that includes additional clinic, treatment and integrative therapy space. The event was open to the public and included a cancer prevention and awareness fair, including information on radon testing and awareness, HPV, genetics and nutrition, as well as colon and breast cancer screening. This expansion was made possible through generous donors and Park Nicollet Foundation’s Love and Legacy campaign.

**Nutrition in Breast Cancer Prevention**
Sponsored a discussion and cooking demonstration on preventing breast cancer. The event took place at Regions Hospital in October 2018.

**Lung Cancer Support Group**
Started in 2017, this monthly group provides an opportunity for patients with lung cancer to connect. There’s a sense of empowerment and belonging when meeting others with a similar cancer diagnosis. The group meets at Regions Hospital. Call 651-254-2426 to learn more.

**Neuro Oncology Summit: Thinking Differently About a Brighter Tomorrow**
One of the highlights of this May 2018 summit was the Support on the Journey segment, which featured neuro oncology patient flow from the hospital to the clinic and beyond.

**Rein in Sarcoma Party in the Park**
This event celebrated sarcoma patients, survivors and their loved ones in July 2018. We were a sponsor.

**Humor to Fight the Tumor**
This September 2018 gala helped raise funds for brain tumor research. We were a gold sponsor.

**Brain Tumor 5K Twin Cities Run & Walk**
We sponsored this event at Lake Phalen in St. Paul to raise funds for brain tumor research in October 2018.

Other organizations and events we supported include Crohn’s and Colitis Foundation, Cancer Legal Care, Irritable Bowel Disease Patient Education Conference and National Football League’s Touch of Football.
Critical to our mission of helping patients with cancer is our engagement in education and research. Teaching and education ensure that our clinicians and staff keep pace with new discoveries in the diagnosis of cancer and treatment. Research, through participation in clinical trials, gives our patients access to new therapies. We’re also taking a leading role in research. We offer a variety of clinical trials at our facilities.

HealthPartners and Park Nicollet co-direct the Metro-Minnesota Community Oncology Research Consortium (mmcorc.org), an affiliation of 22 metro area hospitals. This consortium, sponsored by National Cancer Institute and area hospitals, allows patients in our community to access 100 cancer clinical trials. This program’s administrative center is housed at Park Nicollet. HealthPartners physicians Dan Anderson, MD, and Rich Peterson, MD, are the program’s principal investigator and assistant principal investigator.

In addition, HealthPartners and Park Nicollet Oncology Research Center sponsor a number of on-going clinical trials.

### HEALTHPARTNERS PARK NICOLLET ONCOLOGY RESEARCH CENTER CLINICAL TRIALS

- A Randomized Trial of Medical Cannabis in Patients with Advanced Cancers to Assess Impact on Opioid Use and Cancer-Related Symptoms: A Pilot and Feasibility Study
- AML-03: Pilot Study of IGF-Methotrexate Conjugate in the Treatment of Myelodysplastic Syndrome, CMML, and Oligoblastic AML
- Connect MDS and AML: The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) disease registry
- ARRAY 382-201: A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors
- STM-03: Phase I Study of Procarcase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies
- Array 818-103: A Sequential 2-arm, Open-label Phase I Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cockit Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors
- HCRN MEL16-261: Pilot Study Evaluating Activity of the Combination of Anti-PD-1 Antibody with High Dose IL-2 in Metastatic Melanoma
- OMS-I103 (PISCES): A Multi-center Phase 2, Open-Label Trial of Intratumoral PII-12 Plus Electroporation in Combination with IV Pembrolizumab in Patients with St III/IV Melanoma who are Progressing on either Pembrolizumab Treatment
- HCRN GU15-215: A Randomized Phase II Trial of Atezolizumab with or without Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer
- HCRN LUN15-233: Randomized Phase II Trial of single agent chemotherapy plus Nivolumab or single agent chemotherapy alone in patients with advanced squamous or non-squamous NSCLC with primary resistance to prior PD-1 or PD-L1 inhibitor
- HCRN LUN15-299: Phase II Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma
- MK3475 PN-544: A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects with Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Who Have Failed Pembrolizumab Monotherapy or Who Are Actively Experiencing Stable Disease Following Completion of at least 4 Cycles, of Pembrolizumab Monotherapy
- MK3475-564: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
- PROPEL 16-214-05: A Phase 1B, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination with Anti-PD-1 (pembrolizumab) or Anti-PD-L1 (atezolizumab) in Patients With, Locally Advanced or Metastatic Solid Tumors
- POLARIS A5481082: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study
- TTC-352-101: Study of TTC-352 in Patients with Metastatic Breast Cancer Progressing on Endocrine Therapy
SELECT PUBLICATIONS


SELECT PUBLICATIONS


Palliative care: relief from the symptoms of a serious illness

Palliative care is specialized medical care that focuses on providing relief from the symptoms and stress of a serious illness, including cancer treatment. It’s appropriate at any age and at any stage in serious illness. The goal is to improve the quality of life for the patient and the family.

HealthPartners and Park Nicollet incorporate palliative care specialists and resources into our daily practice, particularly for patients experiencing distressing symptoms or emotions from treatment. Medical studies support the benefits of reduced hospital readmissions, better quality of life, improved symptom control and heightened satisfaction amongst families.

Oncology symposiums provide continuing education

In collaboration with the staff at the Cancer Center of Western Wisconsin, Park Nicollet Frauenshuh Cancer Center and HealthPartners Cancer Care Centers provide oncology education symposiums for health care providers twice yearly.

The spring 2018 symposium on colorectal cancer included these presentations.

- Introduction to Colon Cancer by Karen Rabenau, MD
- Surgical Aspects of Colon Cancer by Ryan Carlson, MD
- Ostomy Care by Jan Chevrette, FNP-C, CWOCN, CFCN
- Inherited Colon Cancer by Katherine Fuhrmann, MS, Certified Genetics Counselor
- Adjuvant Therapy of Colon Cancer by Melissa Sherman, MD
- Treatment of Metastatic Colon Cancer by Balkrishna Jahagirdar, MD

The fall 2018 symposium on caring for lymphoma patients included these presentations.

- Pathologic Classifications & Staging of Malignant Lymphoma by Randy Hurley, MD
- Hodgkin’s Lymphoma by Steve McCormack, MD
- Low Grade Lymphoma by Craig Mescher, MD
- Intermediate and High Grade Lymphoma by Yan Ji, MD
- Review of Primary CNS Lymphoma by Richard Peterson, MD
- CAR T-Cell Therapy, a Primer for RNs by Kurt Demel, MD
Improving care for all patients with cancer

Our staff participates in a number of conferences and training seminars each year to help improve the care of patients with cancer.

HealthPartners Nursing Symposium, April 21, 2018
• Understanding Management of Metastatic Colorectal Cancer by Balkrishna Jahagirdar, MD

Park Nicollet New and Old Drugs: Best Choices, May 3, 2018
• Anemia Treatment 2018 by Bryan Trottier, MD

Park Nicollet Webex, May 30, 2018
• Pearls and Pitfalls: Benign Hematology by Bryan Trottier, MD

International Symposium on Malignant Mesothelioma, June 8, 2018, Minneapolis
• Novel Strategies for Treatment of Mesothelioma after Failure of Front Line Therapy by Arkadiusz Dudek, MD, PhD

HealthPartners Primary Care Pathway Conference, Sept. 21, 2018
• Round and Round: Common Challenges in Hematology by Bryan Trottier, MD

University of Minnesota Fellows’ Core Curriculum, Sept. 24, 2018
• Adjuvant Treatment of Colorectal Cancers by Balkrishna Jahagirdar, MD

University of Minnesota Medical School, Fall, 2018
• How to Survive and Thrive in a Career in Medicine by Jeffrey Jaffe, MD
• Internal Medicine Board Review in Oncology and Hematology by Balkrishna Jahagirdar, MD

Park Nicollet Lunch and Learn, Oct. 11, 2018
• Cannabis for Curious Clinicians – Pearls from a Patient’s Perspective by Dylan Zylla, MD

Society for Immunotherapy of Cancer, Oct. 27, 2018, Minneapolis
• Basic Principles of Cancer Immunotherapy by Arkadiusz Dudek, MD, PhD
• Advances in Immunotherapy of Head and Neck Cancers by Balkrishna Jahagirdar, MD

TRAINING THE NEXT GENERATION OF ONCOLOGISTS

One of the core missions of our organization is to train the next generation of physicians and scientists to be leaders in the field of oncology. Regions Hospital is proud to host clinical training sites for the University of Minnesota Hematology and Oncology Fellowship Program. For more than 25 years, this training has included direct supervision of patient care, didactic lectures and informal teaching sessions. Each year, more than 50 hours of didactic lectures are provided to University of Minnesota medical students, internal medicine residents, hematology-oncology fellows, primary care and emergency room physicians, oncology nurses and pharmacists.
Screening and prevention

BE PINK AND BREAST CANCER AWARENESS
We continued our Be Pink campaign to encourage women in the Twin Cities to be aware, proactive and empowered with their breast health. This includes promoting screenings and early breast cancer detection. Our mobile mammography unit, Mammo-a-go-go, has increased use during the campaign.

HealthPartners, Regions Hospital and Park Nicollet Jane Brattain Breast Center participated again this year in the Susan G. Komen Race for the Cure on Mother's Day 2018. Using our Mammo-a-go-go as a backdrop for our booth space, we had notable event engagement, including people rushing over for our annual charm giveaway.

To kick off breast cancer awareness month in October, we presented Country for a Cause and the Be Pink fundraising breakfast in partnership with the Park Nicollet Foundation. These events benefit the Jane Brattain Breast Center community outreach fund providing mammograms to women in need.

COLORECTAL CANCER SCREENING
As part of Colorectal Cancer Screening Awareness month, a social media campaign and monitor screens in our clinics reminded people to schedule a colorectal screening. To reach even more patients throughout the year, we mailed FIT tests to those who hadn’t been screened in our primary care clinics. FIT tests are an in-home stool sample kit that can be used as a preliminary screening for those who meet certain qualifications.

In September, we sponsored and participated in Get Your Rear in Gear: Tour de Tush race for colon cancer in Minneapolis. Approximately 1,000 participants stopped by our event tent for giveaways and information, including educational materials on FIT testing.

We continued our partnership with Sage, Minnesota’s cancer screening program for low income residents, to screen about 175 patients in 2018.

LUNG CANCER SCREENING
HealthPartners launched a lung cancer screening program in 2017 to identify cancer at an earlier stage to save lives and decrease the cost of lung cancer treatment. Once the patient meets eligibility requirements, the program begins with a shared decision making and counseling session with the patient’s primary care provider. This is followed by a low-dose CT scan. The program also requires results tracking, follow-up activity and submittal to the American College of Radiology (ACR) registry. Studies have shown that this form of secondary prevention can save lives and potentially reduce health care costs.

COMMUNITY WELL-BEING INITIATIVES
According to the American Cancer Society, certain cancer deaths can be prevented by living healthier lifestyles and "making healthy choices like not smoking, staying at a healthy weight, eating right, keeping active and getting recommended screening tests." HealthPartners promotes health and well-being in our communities through a variety of projects and initiatives designed to increase activity, encourage better food and beverage choices and reduce the number of people who use tobacco. With more than 55 primary care clinics across our system, these efforts reach thousands of patients and members each year.

SKIN CANCER SCREENING
Our combined oncology program, in conjunction with our dermatology departments, hosted a free skin cancer screening event for the community May 5, 2018. There were 158 participants, a 27 percent increase over 2017. Follow-up was recommended for nearly 37 percent of participants.

<table>
<thead>
<tr>
<th>Percentage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>35%</td>
<td>Male</td>
</tr>
<tr>
<td>65%</td>
<td>Female</td>
</tr>
<tr>
<td>58</td>
<td>Average age</td>
</tr>
<tr>
<td>18%</td>
<td>Family or personal history of skin cancer</td>
</tr>
<tr>
<td>45%</td>
<td>Tanning bed usage</td>
</tr>
</tbody>
</table>
ACCOUNTABILITY MEASURES

These accountability measures indicate the portion of breast and colorectal cancer patients treated according to recognized standards of care by diagnosis year. The results are reported to the National Cancer Data Base (NCDB), a joint program of American College of Surgeons (ACoS) and American Cancer Society. NCDB is a nationwide oncology outcomes database for more than 1,500 commission-accredited cancer programs.

NCDB Select Breast and Colorectal Measures

<table>
<thead>
<tr>
<th>MEASURE</th>
<th>HEALTHPARTNERS</th>
<th>PARK NICOLLET</th>
<th>NATIONAL BENCHMARK*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiation therapy is administered within one year (365 days) of diagnosis for women under age 70 receiving breast-conserving surgery for breast cancer.</td>
<td>95.5% 93.5% 96.8%</td>
<td>98.5% 98.5% 96.8%</td>
<td>90% **</td>
</tr>
<tr>
<td>Combination chemotherapy is considered or administered within four months (120 days) of diagnosis for women under 70 with AJCC T1c N0 M0, or Stage II or III ER and PR negative breast cancer.</td>
<td>100% 100% 100%</td>
<td>100% 94.1% 85.7%</td>
<td>90%**</td>
</tr>
<tr>
<td>Tamoxifen or third generation aromatase inhibitor is considered or administered within one year (365 days) of diagnosis for women with AJCC T1c N0 M0, or Stage II or III ER and/or PR positive breast cancer.</td>
<td>97.6% 96% 98.1%</td>
<td>97.3% 96.6% 100%</td>
<td>90%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MEASURE</th>
<th>HEALTHPARTNERS</th>
<th>PARK NICOLLET</th>
<th>NATIONAL BENCHMARK*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjuvant chemotherapy is considered or administered within four months (120 days) of diagnosis for patients under the age of 80 with AJCC T1c Stage III (lymph node positive) colon cancer.</td>
<td>100% 83.3% 100%</td>
<td>100% 100% 100%</td>
<td>90% **</td>
</tr>
<tr>
<td>At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.</td>
<td>95.7% 90.6% 98.2%</td>
<td>94% 89.1% 92.27%</td>
<td>85%</td>
</tr>
</tbody>
</table>

*Commission-approved programs  **Noted as 2013 benchmark from NCDB
Oncology registry

MOST COMMON CANCER SITES

The four most common cancers for HealthPartners and Park Nicollet patients in 2017 (excluding skin cancers) were breast, prostate, lung and colorectal. These four sites account for 44 percent and 52 percent of all cases.

In Minnesota, the most common cancers listed in order of occurrence as published in the American Cancer Society’s “Cancer Facts and Figures 2017,” are breast, prostate, lung and colorectal. Table 2 compares by site and percent HealthPartners and Park Nicollet case totals with the estimated number of cases in Minnesota and the U.S.

**TABLE 1:**
2017 Four Most Common Sites by AJCC Stage at HealthPartners and Park Nicollet

<table>
<thead>
<tr>
<th></th>
<th>FEMALE BREAST CANCER</th>
<th>PROSTATE CANCER</th>
<th>COLORECTAL CANCER</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TOTAL CASES: 938</td>
<td>TOTAL CASES: 679</td>
<td>TOTAL CASES: 256</td>
</tr>
<tr>
<td>STAGE 0</td>
<td>187</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>STAGE I</td>
<td>441</td>
<td>192</td>
<td>52</td>
</tr>
<tr>
<td>STAGE II</td>
<td>191</td>
<td>336</td>
<td>43</td>
</tr>
<tr>
<td>STAGE III</td>
<td>66</td>
<td>77</td>
<td>84</td>
</tr>
<tr>
<td>STAGE IV</td>
<td>37</td>
<td>58</td>
<td>56</td>
</tr>
<tr>
<td>UNKNOWN</td>
<td>16</td>
<td>16</td>
<td>14</td>
</tr>
</tbody>
</table>

|                                  | LUNG CANCER          | TOTAL CASES: 441 (MALE 212, FEMALE 229) |
|                                  | STAGE 0              | 1               |
|                                  | STAGE I              | 138             |
|                                  | STAGE II             | 37              |
|                                  | STAGE III            | 69              |
|                                  | STAGE IV             | 186             |
|                                  | UNKNOWN              | 10              |

**TABLE 2:**
2017 Four Most Common Cancer Sites

Table 2 compares, by site and percentage, HealthPartners and Park Nicollet case totals with estimated number of cancer cases in Minnesota and the U.S.

<table>
<thead>
<tr>
<th>CANCER SITE</th>
<th>HEALTHPARTNERS</th>
<th>PARK NICOLLET</th>
</tr>
</thead>
<tbody>
<tr>
<td>BREAST CANCER</td>
<td>15%</td>
<td>23%</td>
</tr>
<tr>
<td>PROSTATE CANCER</td>
<td>12%</td>
<td>16%</td>
</tr>
<tr>
<td>LUNG CANCER</td>
<td>11%</td>
<td>8%</td>
</tr>
<tr>
<td>COLORECTAL CANCER</td>
<td>6%</td>
<td>5%</td>
</tr>
</tbody>
</table>

15% of cancer patients in the United States have breast cancer. 14% in Minnesota

12% of cancer patients in the United States have prostate cancer. 9% in Minnesota

13% of cancer patients in the United States have lung cancer. 12% in Minnesota

8% of cancer patients in the United States have colorectal cancer. 7% in Minnesota
**TABLE 3: 2017 Tumor Registry**

HealthPartners and Park Nicollet tumor registries contain a comprehensive profile of all newly diagnosed cancer using standards set by the American College of Surgeons.

<table>
<thead>
<tr>
<th>CANCER TYPE</th>
<th>HEALTH PARTNERS</th>
<th>PARK NICOLLET</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2016</td>
<td>2017</td>
</tr>
<tr>
<td>ANALYTIC CASES*</td>
<td>1,868</td>
<td>2,049</td>
</tr>
<tr>
<td>NON-ANALYTIC CASES**</td>
<td>90</td>
<td>292</td>
</tr>
<tr>
<td>PERCENTAGE OF CASES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRESENTED AT TUMOR</td>
<td>36.9%</td>
<td>36.4%</td>
</tr>
<tr>
<td>CONFERENCES (GENERAL, GYN, BREAST, LUNG)</td>
<td>(572)</td>
<td>(582)</td>
</tr>
</tbody>
</table>

*Analytic: cases diagnosed and/or having initial therapy at HealthPartners or Park Nicollet

**Non-analytic: cases having all initial therapy elsewhere, seen at HealthPartners or Park Nicollet for further care and treatment

**TABLE 4: 2017 Cancer Cases Diagnoses by Tumor Site and Gender**

<table>
<thead>
<tr>
<th>CANCER TYPE</th>
<th>HEALTH PARTNERS</th>
<th>PARK NICOLLET</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TOTAL</td>
<td>MALE</td>
</tr>
<tr>
<td>ANUS</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>BLADDER</td>
<td>61</td>
<td>41</td>
</tr>
<tr>
<td>BRAIN AND ONS</td>
<td>131</td>
<td>57</td>
</tr>
<tr>
<td>BREAST</td>
<td>310</td>
<td>2</td>
</tr>
<tr>
<td>COLORECTAL</td>
<td>116</td>
<td>74</td>
</tr>
<tr>
<td>ENDOCRINE</td>
<td>59</td>
<td>23</td>
</tr>
<tr>
<td>ESOPHAGUS</td>
<td>22</td>
<td>20</td>
</tr>
<tr>
<td>HEAD &amp; NECK</td>
<td>58</td>
<td>42</td>
</tr>
<tr>
<td>KIDNEY / RENAL</td>
<td>49</td>
<td>35</td>
</tr>
<tr>
<td>LUNG</td>
<td>225</td>
<td>116</td>
</tr>
<tr>
<td>LYMPHOMA</td>
<td>81</td>
<td>38</td>
</tr>
<tr>
<td>MULTIPLE MYELOMA</td>
<td>20</td>
<td>11</td>
</tr>
<tr>
<td>OTHER GI</td>
<td>73</td>
<td>43</td>
</tr>
<tr>
<td>OTHER / ILL-DEFINED</td>
<td>70</td>
<td>36</td>
</tr>
<tr>
<td>OVARY</td>
<td>29</td>
<td>0</td>
</tr>
<tr>
<td>PANCREAS</td>
<td>47</td>
<td>26</td>
</tr>
<tr>
<td>PROSTATE</td>
<td>243</td>
<td>243</td>
</tr>
<tr>
<td>SKIN</td>
<td>240</td>
<td>146</td>
</tr>
<tr>
<td>TESTIS</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>UNKNOWN PRIMARY</td>
<td>14</td>
<td>6</td>
</tr>
<tr>
<td>UTERUS</td>
<td>117</td>
<td>0</td>
</tr>
<tr>
<td>VULVA</td>
<td>25</td>
<td>0</td>
</tr>
<tr>
<td>TOTAL</td>
<td>2,049</td>
<td>999</td>
</tr>
</tbody>
</table>
Quality performance

We continuously measure clinician and system performance to improve quality and to assist in quickly incorporating new medical knowledge into our care.

PATIENT REPORTED OUTCOME SURVEY (PROMS)

This project in oncology aims to collect outcome metrics on symptoms from patients at clinic visits, before and after chemotherapy. The project utilizes a validated symptom survey tool which is sent to patients through automated emails and electronic collection methods at the point of care. Oncology patients have the opportunity to complete the survey at home. If patients are not able to complete the survey prior to an appointment, they will be asked to complete the PROMS via iPad. The PROMS system sends data to EPIC upon user completion of the survey. This allows the care team to see and monitor symptoms in real time.

BEACON ORAL CHEMOTHERAPY INITIATIVE

This initiative allows oncologists to order oral chemotherapy in the same way infused chemotherapy is ordered. The goal is to provide consistency in the ordering and documentation process. The oral chemotherapy initiative went live in November 2018.

CARING FOR PATIENTS WITH DIABETES AND CANCER

The goal is to improve clinical outcomes for patients with diabetes and cancer receiving chemotherapy with steroid medications. A pilot program is underway to improve risk assessment and detection of patients with diabetes as well as understand the scope of problems and areas of focus. The results will be used to create a diabetes intervention initiative in our cancer centers.

IMPROVE WELL PROJECT

This quality improvement work focused on reducing delays in receiving chemotherapy at Regions Hospital Cancer Care Center. The goal was to decrease average infusion wait times from Beacon chemotherapy plan approval to starting treatment.

QUALITY ACADEMY AKI WITH CISPLATIN

Cisplatin-associated nephrotoxicity is unpredictable but associated with significant morbidity and mortality. It has the potential to diminish quality of life and compromise treatment. The team’s aim is to minimize Cisplatin-associated nephrotoxicity by implementing renal-protective measures and a risk stratification model into Beacon protocols.

Dedicated to providing excellent care

On average, 95.6 percent of patients would recommend our providers. That exceeds the national average of 84.3 percent, according to the National Research Council. Other ratings by our patients include:

- Would recommend: 95.5%
- Rate your provider: 90.4%
- Provider listened: 97.0%
- Provider knew my medical history: 93.4%
- Provider showed respect for what the patient said: 97.5%
Give hope. Give possibility.

In 2017, through Regions Hospital Foundation and Park Nicollet Foundation, 1,046 donors gave more than $500,000 to support meaningful care for those affected by cancer at Regions Cancer Center and Park Nicollet Frauenshuh Cancer Center.

Park Nicollet Foundation

Donors make it happen
You ensure the sustainability of Frauenshuh Cancer Center programs, including:

- Clinical cancer research
- Music, massage and other therapies
- Non-moving patient care model
- Patient special needs
- Patient support groups and education
- Survivorship program

Be a part of our mission in action
Contact Park Nicollet Foundation at 952-993-5023 or foundation@parknicollet.com.

Regions Hospital Foundation

Donors bring hope to patients with cancer
Your generous gifts to Regions Hospital Cancer Care Center support:

- Basic needs assistance
- Care navigation assistance
- Classes and support groups
- Clinical cancer research
- Music and massage therapy

Find out how you can make a difference
Contact Regions Hospital Foundation at 651-254-2376 or rhf@healthpartners.com.

“My wife and I were both treated really well by Frauenshuh Cancer Center. If by donating, I am able to make sure other patients have the best care, then it serves my wife’s memory, and it means a lot to me.”

– GARY, CAREGIVER, CANCER SURVIVOR, DONOR, VOLUNTEER

“We want to help others focus on living while they’re undergoing treatment.”

– MEGAN GANGL

Megan Gangl and the Mahtomedi High School Track team raise money each year to support fun family activities for Regions Hospital patients receiving cancer treatment.
Cancer committee members 2018

Our cancer committees meet quarterly to review all aspects of our program. This includes information related to cancer conferences, community outreach, research and quality improvement, as well as all the teams involved in cancer care.

| HEALTHPARTNERS | | PARK NICOLLET | | | |
|---|---|---|---|---|
| Sue Braaten, RHIT, CTR | Oncology Registry | Christopher Chow, MD | Colon and Rectal Surgery | Anne Hopkins, RN, OCN |
| Dion Christensen Johnston, RN, OCN | Nurse Manager, Cancer Center | Justin Eklund | Clinical Research | Christian Loger |
| Linda Christensen-Rengel, NP | Breast Health Center | Britt Erickson, MD | Gynecologic Oncology | Jane Brattain Breast Center |
| Christine Colbach, MD | Pathology | Jim Ferguson | Chaplain | Pamela Mason |
| Kevin Collis, RN, OCN | Nurse Navigator | Kelly Furda, MD | Radiologist | American Cancer Society |
| Kim Duffy, RD | Food and Nutritional Services | Nancy Gelle, BSN, RN | Palliative Care, Hospice | Matt McCoy, MD |
| Holly Guida, RN-BSN, MBA | Oncology Operations Specialist | Howard Haines, MN | Emergency Medicine | Pathology |
| Laura Holasek | Director, Cancer Center | Michael Haley, MD | Radiation Oncology | Vicki Norton, BSN, OCN, RN |
| Randy Hurley, MD | Medical Oncology | Kristin Hanrahan | Quality Improvement | Nursing |
| Cindy Johnston | Genetic Counselor | James Risser, MD | Internal Medicine, Palliative Care | Carol Ann Petersen, LICSW, MAHS |
| Karen Lin, CTR | Cancer Registry | James Schlaefer, MD | General Surgery, Surgical Oncology (Cancer Liaison Fellow, American College of Surgeons) | Patient Support and Education |
| Rory Malloy | Quality Management | Rob Ruff | Pastoral Care | Jocelyn Rieder, MD |
| Pam Mason | American Cancer Society | Charles Shideman, MD | Radiation, Oncology | Urology |
| | | Amanda Richards, RN, OCN, BSN | Research | Emily Schoh, RN |
| | | | | Nursing |
| | | | | Bryan Schuler, PharmD, BCOP |
| | | | | Pharmacy |
| | | | | Jane Siekkinen, BS, CTR |
| | | | | Oncology Registry |
| | | | | Paul Spilde, PT |
| | | | | Rehabilitation Services |
| | | | | Eric Weinberg, MD |
| | | | | Diagnostic Radiology |
| | | | | Mark Wilkowske, MD |
| | | | | Medical Oncology |
Oncology provider team

Caroline Abenakyo, MA, NP-F
Daniel Anderson, MD
Peter Argenta, MD
Kacy Berquist, MSN, APRN, NP-C
Linda Carson, MD
Joel Carter, MD
Cathleen Chen, MD
Janel Cox, MD
Kurt Demel, MD
Arkadiusz Dudek, MD, PhD
Mary Ehresman, FNP, ADCN
Britt Erickson, MD
Brad Farrell, PharmD
Lori Fewer, CFNP
Chitra Ganesan, MBBS
Monique Giordana, PharmD
Michael Haley, DO
Robert Haselow, MD
Keith Heaton, MD
Jason Hoiness, PharmD
Peter Hurley, MD
Randy Hurley, MD
Lisa Huset, PA-C
Gretchen Ibele, MD
Lisa Illig, MD
Jeffry Jaffe, MD
Balkrishna Jahagirdar, MD
Kathryn Jelle, PA-C
Yan Ji, MD
Carol Jirik, RN
Stephanie Kroon, PA-C
Kendra Kubiak, MD
Priya Kumar, MD
Brenda Larson, MD
Rachel Lerner, MD
Ayse Malcolm, MD
Sarah Manuels, MPAS, PA-C, MPH
Steven McCormack, MD
Mark Menge, MD
Craig Mescher, MD
Kathryn Moore, MD
Sally Mullany, MD
Gretchen Niemoja, MD
Jason Oakes, PA-C
Adina Peck, ANP, GNP
Richard Peterson, MD
Karen Rabenau, MD
Brian Rank, MD
Anne Reiber, ANP, GNP
Daniel Schneider, MD
Melissa Sherman, MD
Gary Shapiro, MD
Charles Shideman, MD
Mary Spengler, RNC, ANP
Amy Spomer, MD
Cierra Sroda, PA-C
Somu Suppiah, MD
Deanna Teoh, MD
Jane Thompson, PharmD
Kandice Tolic, NP-WH
Bryan Trottier, MD
Punit Wadhwa, MBBS
Mark Wilkowske, MD
Dylan Zylla, MD, MS
HealthPartners Institute
Advancing health and health care

HealthPartners Institute is a 501c3 non-profit organization with researchers dedicated to conducting high-quality, public-domain health research. The institute is an affiliate member of Cancer Research Network (CRN) and a participant in the National Cancer Institute-funded CRN IV program. HealthPartners research includes projects and initiatives of Park Nicollet. Pamala Pawloski, PharmD, is the site primary investigator and a CRN scholar, a role that allows her to be a mentor to new investigators. Visit healthpartners.com/institute to learn more.

To make an appointment, call:

Park NicolletFrauenshuh Cancer Center 952-993-3248
Regions Hospital Cancer Care Center 651-254-3572
HealthPartners Cancer Care Center – Riverside 612-341-4800

Park Nicollet Clinic & Specialty Center – Burnsville 952-993-3248
Park Nicollet Clinic & Specialty Center – Maple Grove 952-993-3248

For more information or to make a referral, contact Laura Holasek at laura.holasek@parknicollet.com or 651-254-4656